Evidence Room
Bank now. Expansion makes it useful. The field is real. Your own cells are the safe way in.
- 01SupportedHigh confidence
Your stem cells will never be younger: potency declines with age — and no technology restores it.
Growth capacity, expansion headroom, and senescence burden decline with donor age. That is what banking and expansion actually depend on.
7 studies for · 3 against · Last reviewed August 26, 2026
- 02SupportedModerate-to-High confidence
Culture-expanded MSCs outperform same-day procedures — because structural outcomes require doses only expansion can reach.
A typical aspirate yields roughly 0.5–2 million MSCs. Outcomes cluster at 20–100 million cells. That dose is physically unreachable without expansion.
4 studies for · 0 against · Last reviewed August 26, 2026
- 03SupportedHigh confidence
MSC therapy outperforms PRP for degenerative joint and tendon conditions.
The strongest comparative evidence in the room for culture-expanded MSCs in degenerative joint and tendon disease, including knee osteoarthritis.
2 studies for · 0 against · Last reviewed August 26, 2026
- 04SupportedHigh confidence
Your own cells are the safest cells: autologous MSC therapy minimizes immune risk.
No donor matching, no alloimmunization, no donor-disease transmission. Allogeneic cells carry a documented donor-specific antibody rate — most relevant for the multi-dose future expansion enables.
1 study for · 0 against · Last reviewed August 26, 2026
Physician? Think we've missed a study — for or against? Tell us: info@foreverlabs.com.